Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2026)

Black Diamond Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $28.6 million for Q1 2026.

• Quarterly Total Liabilities fell 17.58% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (down 17.58% YoY) and the FY2025 annual result came in at $30.8 million, down 21.74% from the prior year.
• Total Liabilities was $28.6 million for Q1 2026 at Black Diamond Therapeutics, down from $30.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $47.2 million in Q3 2022 and bottomed at $28.6 million in Q1 2026.
• A 5-year average of $38.4 million and a median of $38.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 44.35% — and 2025, when it dropped 21.96%.
• Black Diamond Therapeutics' Total Liabilities stood at $40.6 million in 2022, then climbed by 3.13% to $41.8 million in 2023, then fell by 5.92% to $39.4 million in 2024, then decreased by 21.74% to $30.8 million in 2025, then slipped by 7.07% to $28.6 million in 2026.
• Business Quant data shows BDTX's Total Liabilities at $28.6 million in Q1 2026, $30.8 million in Q4 2025, and $31.6 million in Q3 2025.